FoRx Therapeutics is a privately-held biotechnology company focused on developing first-in-class cancer therapeutics by targeting DNA replication stress and DNA damage response pathways. Based in Basel, Switzerland, the team combines expertise in cancer biology, genomics, biochemistry, medicinal chemistry, and small molecule drug discovery to identify molecular targets involved in replication fork repair for targeted anticancer drugs.